This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Arena: FDA Adds Obesity Docs to Panel

Stocks in this article: ARNA VVUS OREX

BOSTON ( TheStreet) -- Thoughts and observations on obesity drug stocks as Arena Pharmaceuticals (ARNA) gets ready to bring lorcaserin in front an another FDA advisory panel on May 10.

My apologies for beginning with some shameless self promotion: I will be live-blogging the Arena FDA panel, providing eight hours-plus of continuous, play-by-play coverage and instant analysis as obesity experts review and ultimately pass judgment on lorcaserin's efficacy and safety.

Don't miss out on all the excitement and suspense. More than 22,000 readers logged into my live blog of the Vivus (VVUS) FDA panel in February, which resulted in a 20-2 vote in favor of Qnexa. I expect another big crowd on May 10, so mark your calendars.

FDA has not yet announced the final roster for the upcoming Arena panel but five obesity experts have accepted invitations to participate, according to a memo posted to the agency's web site. One of these five obesity experts is Dr. Daniel Bessesen, a professor of endocrinology at the University of Colorado School of Medicine. Bessesen received a conflict of interest waiver to participate on the Arena panel because he's a member of a data safety monitoring board for a competing (but undisclosed) weight-loss therapy.

The identities of the remaining four obesity experts invited by FDA to sit on the Arena panel have not been disclosed but the agency said one is a clinical endocrinologist (like Bessesen); the others are a bariatrician, a pediatric endocrinologist and epidemiologist.

These five obesity experts will beef up the 10 sitting experts on the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC), six of whom are also endocrinologists or have relevant expertise in diabetes and obesity.

Key question for next week: Does an FDA panel stacked heavily with obesity drug experts help or hurt lorcaserin's chances for a positive vote?

Eight endocrinologists/obesity experts sat on the Vivus FDA panel in February, with all but one voting to recommend Qnexa's approval. The overall panel vote was 20-2 in Qnexa's favor.

Qnexa won in large part because treatment led to significant, clinically meaningful weight loss, which outweighed the potential risk of causing birth defects in children born to women using the two-drug therapy.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs